10 in patients with Statin-Induced Myalgia: Retrospective case review">
Home | About us | Editorial board | Search | Ahead of print | Current issue | Archives | Submit article | Instructions | Subscribe | Contacts | Advertise | Login 
 
Search Article 
  
Advanced search 
  Users Online: 457 Home Print this page Email this page Small font sizeDefault font sizeIncrease font size  
BRIEF COMMUNICATION
Year : 2012  |  Volume : 16  |  Issue : 8  |  Page : 498-500

Oral use of "Low and Slow" Rosuvastatin with Co-Enzyme Q 10 in patients with Statin-Induced Myalgia: Retrospective case review


1 Specialist Trainee in Endocrinology and Diabetes, Royal London Hospital, London, United Kingdom
2 Core Medical Trainee, Department of Diabetes and Metabolism, Royal London Hospital, London, United Kingdom
3 Training in General (Internal) Medicine, Diabetes and Endocrinology in Birmingham and Manchester

Correspondence Address:
Madhurima Vidyarthi
Specialist Trainee in Endocrinology and Diabetes, Royal London Hospital, London
United Kingdom
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/2230-8210.104144

Rights and Permissions

Background: Statins have proven efficacy in reducing vascular disease, but statin-induced myalgia is relatively common in clinical practice, and can sometimes leave patients who are high risk for vascular disease unable to take these important preventative treatments. Low or intermittent dose rosuvastatin has been shown to be useful in lowering cholesterol with fewer side-effects. Supplementation with co-enzyme Q 10 is suggested to reduce statin-induced myalgia. Materials and Methods: A retrospective review of patients attending a tertiary referral lipid clinic with statin-induced myalgia was carried out. Patients were counseled on commencing low-dose rosuvastatin, titrated at monthly intervals, and supplemented by co-enzyme Q 10 100 mg daily. Results: Forty Three patients were reviewed. Six were unable to tolerate the regime at all. The remaining 37 patients tolerated rosuvastatin between 5 mg weekly and 20 mg daily. Total and LDL-cholesterol levels fell by a mean of 29.1% and 27.5%, respectively. 62.2% of patients achieved total cholesterol under 5.0 mmol/L. Conclusions: In this retrospective review of clinical practice, "low and slow" rosuvastatin supplemented by co-enzyme Q 10 led to clinically meaningful reductions in total and LDL-cholesterol in patients with statin-induced myalgia.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed3541    
    Printed29    
    Emailed0    
    PDF Downloaded204    
    Comments [Add]    

Recommend this journal